Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A

Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A

India Pharma Outlook Team | Wednesday, 15 January 2025

Rappta Therapeutics (Rappta), focused to creating first-in-class anti-cancer therapies that activate protein phosphatase 2A (PP2A), has announced a global exclusive licensing agreement with SpringWorks Therapeutics (SpringWorks) for RPT04402, a novel molecular glue targeting specific Protein Phosphatase 2A (PP2A) complexes.

Rappta’s technologies that reactivate PP2A, created from its unique high-resolution structural information, have the potential to develop a new category of anti-cancer medications for addressing a wide array of human cancers. PP2A is an essential enzyme involved in the regulation of protein de-phosphorylation, and its reactivation is vital for tumour suppression; however, it has traditionally been challenging to target.

PP2A mutations act as oncogenic drivers in specific molecular subsets of uterine cancer and signify a targetable group of patients with significant clinical needs. In pre-clinical models of uterine cancer with PP2A mutations, RPT0402 resulted in quick, significant, and long-lasting tumor reductions as a standalone treatment.

Sunjeet Sawhney, chief executive officer of Rappta Therapeutics, commented: “Rappta is the only company to have successfully targeted PP2A, a notoriously difficult and undruggable target. Data we generated demonstrated the potential of RPT04402 for treating large, underserved patient populations. SpringWorks, a leader in the targeted oncology space, has the expertise and knowledge to accelerate the further development of our first in class asset. I would like to thank our team and investors who have supported our journey and we look forward to following the progress made in this area”

on the deck

Most Viewed

Related Articles


© 2025 India Pharma Outlook. All Rights Reserved.